Zepbound 2.5mg

First-In-Class Dual-Agonist Therapy: The Starting Point for Weight Management

Zepbound™ 2.5mg introduces patients to a groundbreaking approach in medical weight management. As the initiation dose of tirzepatide—the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved specifically for chronic weight management—this starting strength represents the beginning of a novel therapeutic pathway distinct from diabetes treatment. Designed for a four-week initiation period, the 2.5mg dose allows for gradual acclimation to the medication’s dual hormonal activity while minimizing initial gastrointestinal side effects. Delivered via a single-patient-use pre-filled pen, this starting dose activates both GIP and GLP-1 receptors at a gentle level, setting the foundation for the significant weight reduction benefits demonstrated in the SURMOUNT clinical trial program.

Dual-Incretin Mechanism: Gentle Introduction to Appetite Regulation

The 2.5mg starting dose of Zepbound™ begins engaging both the GIP and GLP-1 metabolic pathways—a unique mechanism that distinguishes it from single GLP-1 receptor agonists for weight management. At this initial strength, tirzepatide starts to enhance feelings of fullness, slow gastric emptying, and influence central nervous system pathways that control hunger and food reward signaling while simultaneously activating GIP receptors that may improve insulin sensitivity and fat metabolism. Patients often notice early effects on appetite control, reduced cravings, and easier portion management during these first weeks. This gradual introduction at 2.5mg is clinically proven to significantly improve gastrointestinal tolerability, with studies showing markedly reduced incidence of nausea and other digestive side effects compared to starting at higher doses, thereby supporting patient adherence from treatment inception.

Key Features of the 2.5mg Initiation Dose:

• Dual-Receptor Introduction: Begins activating both GIP and GLP-1 receptors—the only weight management treatment with this dual mechanism of action.

• Tolerability-Optimized Start: Specifically designed as a four-week starting dose to minimize gastrointestinal side effects while the body adapts to dual-incretin activity.

• Pathway to Substantial Efficacy: Serves as the essential first step toward achieving the significant weight loss (15-20%+ average) demonstrated at higher maintenance doses in the SURMOUNT clinical trials.

• Structured Treatment Foundation: Follows the FDA-approved and manufacturer-recommended titration schedule: 2.5mg for 4 weeks, followed by escalation to 5mg.

• Familiar Administration System: Uses the same Zepbound™ single-use pre-filled pen available at all dose strengths, allowing patients to establish their weekly injection routine from day one.

Clinical Protocol & Important Safety Information:

• Dosage Schedule: One subcutaneous injection of 2.5mg once weekly for the first four weeks of treatment. Administer on the same day each week, with or without food.

• Injection Instructions: Use the Zepbound™ single-use pre-filled pen. Inject into the abdomen, thigh, or upper arm. Rotate injection sites each week.

• Mandatory Titration: After four weeks at 2.5mg, the dose MUST be increased to 5mg once weekly to achieve therapeutic efficacy. The 2.5mg dose is for initiation only and is not effective for long-term weight management.

• Common Initiation Side Effects: Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain may occur. These are usually mild to moderate and tend to decrease over time.

• Boxed Warning: Risk of thyroid C-cell tumors. Zepbound™ is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Additional Warnings & Precautions: Pancreatitis, hypoglycemia (when used with insulin or insulin secretagogues), severe gastrointestinal disease, acute gallbladder disease, acute kidney injury, and suicidal behavior or ideation have been reported. Monitor for depression or suicidal thoughts.

• Prescription Requirement: Zepbound™ is available only by prescription. Treatment requires comprehensive medical assessment, including evaluation of personal and family medical history, and ongoing medical supervision.